AAP
CSCI

Ardsley Advisory Partners’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Ardsley Advisory Partners’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-250
Closed -$74K – 151
2018
Q4 		$74K Buy
+250
New +$59.8K 0.02% 99

Other funds holding CSCI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return

Ardsley Advisory Partners's CSCI Position: Q1 2019 in Review

Ardsley Advisory Partners sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q1 2019, closing a stake of 250 shares — an estimated $74K sold.

Ardsley Advisory Partners first reported a position in CSCI in Q4 2018 and held it in 1 quarter. The position peaked at $74K in Q4 2018. 26 funds tracked by Wall St. Rank hold CSCI as of Q1 2019.

  • Ardsley Advisory Partners reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Ardsley Advisory Partners sold 250 COSCIENS Biopharma Inc. Common Stock shares in Q1 2019, an estimated $74K.
  • Ardsley Advisory Partners first reported a position in COSCIENS Biopharma Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Ardsley Advisory Partners's COSCIENS Biopharma Inc. Common Stock position peaked at $74K in Q4 2018.
  • 26 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q1 2019.

Based on Ardsley Advisory Partners's 13F filing for Q1 2019, filed 15 May 2019.